ROKIT Healthcare, a South Korean company specializing in AI-powered hyper-personalized organ regeneration platforms, has signed a strategic memorandum of understanding (MOU) with Master Investment Group (MIG), a UAE royal family-backed investment institution, for a direct equity investment worth approximately $20.7M USD (KRW 30 billion) and the establishment of a joint venture (JV) in the UAE.

Notably, amid ongoing geopolitical tensions in the Middle East, H.H. Sheikh Abdullah bin Mohammed bin Sakr Al Qasimi, CEO of the Ras Al Khaimah (RAK) royal family and representative of MIG, personally traveled to ROKIT Healthcare’s headquarters in Seoul to verify the company’s AI-driven organ regeneration and anti-aging technology firsthand and discuss the future business vision — a move that underscored his strong commitment to the partnership.

The two parties have agreed to finalize a detailed investment agreement in the near term and proceed with establishing a local manufacturing facility and joint venture. MIG will contribute approximately $20.7M USD (KRW 30 billion) in capital for the planned Middle East joint venture, tentatively named ROKIT MENA, while ROKIT Healthcare will contribute its core AI organ regeneration platform technology as an in-kind investment. MIG, which serves as an anchor investor driving the attraction of strategic industries and infrastructure development, has previously made early-stage investments in global deep tech companies including Nauticus Robotics.

The newly established JV is set to secure a foothold in the UAE as a base for AI-based regenerative medicine clinics and local commercial production. From there, it plans to expand its medical network to major Gulf Cooperation Council (GCC) countries, including Saudi Arabia, and further into European markets. By entering the GCC market — estimated to have approximately 15 million potential patients — ROKIT Healthcare completes a global direct-sales triangle spanning the United States, China, and the Middle East and Europe.

“Sheikh Abdullah’s personal visit to Korea, even amid serious international tensions, is a testament to the overwhelming value of our AI regenerative medicine technology,” said Yoo Seok-hwan, CEO of ROKIT Healthcare. “With this large-scale investment and JV establishment as a turning point, ROKIT Healthcare will leap forward as a game-changer leading the global AI organ regeneration field.”